請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/51206
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 蕭寧馨(Ning-Sing Shaw) | |
dc.contributor.author | Yi-Ting Tsai | en |
dc.contributor.author | 蔡宜廷 | zh_TW |
dc.date.accessioned | 2021-06-15T13:27:28Z | - |
dc.date.available | 2026-12-31 | |
dc.date.copyright | 2016-02-24 | |
dc.date.issued | 2016 | |
dc.date.submitted | 2016-02-15 | |
dc.identifier.citation | (1) Brown, J. M.; Giaccia, A. J. 'The unique physiology of solid tumors: opportunities (and problems) for cancer therapy.' Cancer Research 1998, 58, 1408-1416.
(2) Hockel, M.; Schlenger, K.; Aral, B.; Mitze, M.; Schaffer, U.; Vaupel, P. 'Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix.' Cancer Research 1996, 56, 4509-4515. (3) Brizel, D. M.; Scully, S. P.; Harrelson, J. M.; Layfield, L. J.; Bean, J. M.; Prosnitz, L. R.; Dewhirst, M. W. 'Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma.' Cancer Research 1996, 56, 941-943. (4) Cuvier, C.; Jang, A.; Hill, R. P. 'Exposure to hypoxia, glucose starvation and acidosis: effect on invasive capacity of murine tumor cells and correlation with cathepsin (L + B) secretion.' Clinical and Experimental Metastasis 1997, 15, 19-25. (5) Graham, C. H.; Forsdike, J.; Fitzgerald, C. J.; Macdonald-Goodfellow, S. 'Hypoxia-mediated stimulation of carcinoma cell invasiveness via upregulation of urokinase receptor expression.' International Journal of Cancer 1999, 80, 617-623. (6) Sundfor, K.; Lyng, H.; Rofstad, E. K. 'Tumour hypoxia and vascular density as predictors of metastasis in squamous cell carcinoma of the uterine cervix.' British Journal of Cancer 1998, 78, 822-827. (7) Gray, L. H.; Conger, A. D.; Ebert, M.; Hornsey, S.; Scott, O. C. 'The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy.' British Journal of Radiology 1953, 26, 638-648. (8) Teicher, B. A. 'Hypoxia and drug resistance.' Cancer and Metastasis Reviews 1994, 13, 139-168. (9) Tredan, O.; Galmarini, C. M.; Patel, K.; Tannock, I. F. 'Drug resistance and the solid tumor microenvironment.' Journal of the National Cancer Institute 2007, 99, 1441-1454. (10) Vaupel, P.; Kallinowski, F.; Okunieff, P. 'Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review.' Cancer Research 1989, 49, 6449-6465. (11) Harris, A. L. 'Hypoxia--a key regulatory factor in tumour growth.' Nature Reviews: Cancer 2002, 2, 38-47. (12) Denko, N. C. 'Hypoxia, HIF1 and glucose metabolism in the solid tumour.' Nature Reviews: Cancer 2008, 8, 705-713. (13) Lanzen, J.; Braun, R. D.; Klitzman, B.; Brizel, D.; Secomb, T. W.; Dewhirst, M. W. 'Direct demonstration of instabilities in oxygen concentrations within the extravascular compartment of an experimental tumor.' Cancer Research 2006, 66, 2219-2223. (14) Olive, P. L.; Vikse, C.; Trotter, M. J. 'Measurement of oxygen diffusion distance in tumor cubes using a fluorescent hypoxia probe.' International Journal of Radiation Oncology, Biology, Physics 1992, 22, 397-402. (15) Torres Filho, I. P.; Leunig, M.; Yuan, F.; Intaglietta, M.; Jain, R. K. 'Noninvasive measurement of microvascular and interstitial oxygen profiles in a human tumor in SCID mice.' Proceedings of the National Academy of Sciences of the United States of America 1994, 91, 2081-2085. (16) Kobayashi, H.; Watanabe, R.; Choyke, P. L. 'Improving conventional enhanced permeability and retention (EPR) effects; what is the appropriate target?' Theranostics 2013, 4, 81-89. (17) Carreau, A.; El Hafny-Rahbi, B.; Matejuk, A.; Grillon, C.; Kieda, C. 'Why is the partial oxygen pressure of human tissues a crucial parameter? Small molecules and hypoxia.' Journal of Cellular and Molecular Medicine 2011, 15, 1239-1253. (18) Cassavaugh, J.; Lounsbury, K. M. 'Hypoxia-mediated biological control.' Journal of Cellular Biochemistry 2011, 112, 735-744. (19) Nussenbaum, F.; Herman, I. M. 'Tumor angiogenesis: insights and innovations.' Journal of Oncology 2010, 2010, 132641. (20) Rankin, E. B.; Giaccia, A. J. 'The role of hypoxia-inducible factors in tumorigenesis.' Cell Death and Differentiation 2008, 15, 678-685. (21) Warburg, O. 'On the origin of cancer cells.' Science 1956, 123, 309-314. (22) Rofstad, E. K. 'Microenvironment-induced cancer metastasis.' International Journal of Radiation Biology 2000, 76, 589-605. (23) Erler, J. T.; Bennewith, K. L.; Nicolau, M.; Dornhofer, N.; Kong, C.; Le, Q. T.; Chi, J. T.; Jeffrey, S. S.; Giaccia, A. J. 'Lysyl oxidase is essential for hypoxia-induced metastasis.' Nature 2006, 440, 1222-1226. (24) Chan, D. A.; Giaccia, A. J. 'Hypoxia, gene expression, and metastasis.' Cancer and Metastasis Reviews 2007, 26, 333-339. (25) Zhang, L.; Hill, R. P. 'Hypoxia enhances metastatic efficiency by up-regulating Mdm2 in KHT cells and increasing resistance to apoptosis.' Cancer Research 2004, 64, 4180-4189. (26) Zhang, L.; Hill, R. P. 'Hypoxia enhances metastatic efficiency in HT1080 fibrosarcoma cells by increasing cell survival in lungs, not cell adhesion and invasion.' Cancer Research 2007, 67, 7789-7797. (27) McKeown, S. R. 'Defining normoxia, physoxia and hypoxia in tumours-implications for treatment response.' British Journal of Radiology 2014, 87, 20130676. (28) Hockel, M.; Vaupel, P. 'Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects.' Journal of the National Cancer Institute 2001, 93, 266-276. (29) Vaupel, P.; Hockel, M.; Mayer, A. 'Detection and characterization of tumor hypoxia using pO2 histography.' Antioxid Redox Signal 2007, 9, 1221-1235. (30) Nordsmark, M.; Bentzen, S. M.; Overgaard, J. 'Measurement of human tumour oxygenation status by a polarographic needle electrode. An analysis of inter- and intratumour heterogeneity.' Acta Oncologica 1994, 33, 383-389. (31) Becker, A.; Hansgen, G.; Bloching, M.; Weigel, C.; Lautenschlager, C.; Dunst, J. 'Oxygenation of squamous cell carcinoma of the head and neck: comparison of primary tumors, neck node metastases, and normal tissue.' International Journal of Radiation Oncology, Biology, Physics 1998, 42, 35-41. (32) Le, Q. T.; Kovacs, M. S.; Dorie, M. J.; Koong, A.; Terris, D. J.; Pinto, H. A.; Goffinet, D. R.; Nowels, K.; Bloch, D.; Brown, J. M. 'Comparison of the comet assay and the oxygen microelectrode for measuring tumor oxygenation in head-and-neck cancer patients.' International Journal of Radiation Oncology, Biology, Physics 2003, 56, 375-383. (33) Falk, S. J.; Ward, R.; Bleehen, N. M. 'The influence of carbogen breathing on tumour tissue oxygenation in man evaluated by computerised p02 histography.' British Journal of Cancer 1992, 66, 919-924. (34) Le, Q. T.; Chen, E.; Salim, A.; Cao, H.; Kong, C. S.; Whyte, R.; Donington, J.; Cannon, W.; Wakelee, H.; Tibshirani, R.; Mitchell, J. D.; Richardson, D.; O'Byrne, K. J.; Koong, A. C.; Giaccia, A. J. 'An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers.' Clinical Cancer Research 2006, 12, 1507-1514. (35) Vaupel, P.; Mayer, A.; Briest, S.; Hockel, M. 'Oxygenation gain factor: a novel parameter characterizing the association between hemoglobin level and the oxygenation status of breast cancers.' Cancer Research 2003, 63, 7634-7637. (36) Hockel, M.; Schlenger, K.; Knoop, C.; Vaupel, P. 'Oxygenation of carcinomas of the uterine cervix: evaluation by computerized O2 tension measurements.' Cancer Research 1991, 51, 6098-6102. (37) Koong, A. C.; Mehta, V. K.; Le, Q. T.; Fisher, G. A.; Terris, D. J.; Brown, J. M.; Bastidas, A. J.; Vierra, M. 'Pancreatic tumors show high levels of hypoxia.' International Journal of Radiation Oncology, Biology, Physics 2000, 48, 919-922. (38) Graffman, S.; Bjork, P.; Ederoth, P.; Ihse, I. 'Polarographic pO2 measurements of intra-abdominal adenocarcinoma in connection with intraoperative radiotherapy before and after change of oxygen concentration of anaesthetic gases.' Acta Oncologica 2001, 40, 105-107. (39) Movsas, B.; Chapman, J. D.; Hanlon, A. L.; Horwitz, E. M.; Pinover, W. H.; Greenberg, R. E.; Stobbe, C.; Hanks, G. E. 'Hypoxia in human prostate carcinoma: an Eppendorf PO2 study.' American Journal of Clinical Oncology 2001, 24, 458-461. (40) Parker, C.; Milosevic, M.; Toi, A.; Sweet, J.; Panzarella, T.; Bristow, R.; Catton, C.; Catton, P.; Crook, J.; Gospodarowicz, M.; McLean, M.; Warde, P.; Hill, R. P. 'Polarographic electrode study of tumor oxygenation in clinically localized prostate cancer.' International Journal of Radiation Oncology, Biology, Physics 2004, 58, 750-757. (41) Movsas, B.; Chapman, J. D.; Horwitz, E. M.; Pinover, W. H.; Greenberg, R. E.; Hanlon, A. L.; Iyer, R.; Hanks, G. E. 'Hypoxic regions exist in human prostate carcinoma.' Urology 1999, 53, 11-18. (42) Vaupel, P.; Thews, O.; Mayer, A.; Hockel, S.; Hockel, M. 'Oxygenation status of gynecologic tumors: what is the optimal hemoglobin level?' Strahlentherapie und Onkologie 2002, 178, 727-731. (43) Vaupel, P.; Mayer, A.; Hockel, M. 'Oxygenation status of primary and recurrent squamous cell carcinomas of the vulva.' European Journal of Gynaecological Oncology 2006, 27, 142-146. (44) Stone, J. E.; Parker, R.; Gilks, C. B.; Stanbridge, E. J.; Liao, S. Y.; Aquino-Parsons, C. 'Intratumoral oxygenation of invasive squamous cell carcimoma of the vulva is not correlated with regional lymph node metastasis.' European Journal of Gynaecological Oncology 2005, 26, 31-35. (45) Lartigau, E.; Randrianarivelo, H.; Avril, M. F.; Margulis, A.; Spatz, A.; Eschwege, F.; Guichard, M. 'Intratumoral oxygen tension in metastatic melanoma.' Melanoma Research 1997, 7, 400-406. (46) Lawrentschuk, N.; Poon, A. M.; Foo, S. S.; Putra, L. G.; Murone, C.; Davis, I. D.; Bolton, D. M.; Scott, A. M. 'Assessing regional hypoxia in human renal tumours using 18F-fluoromisonidazole positron emission tomography.' BJU International 2005, 96, 540-546. (47) Mattern, J.; Kallinowski, F.; Herfarth, C.; Volm, M. 'Association of resistance-related protein expression with poor vascularization and low levels of oxygen in human rectal cancer.' International Journal of Cancer 1996, 67, 20-23. (48) Wilson, W. R.; Hay, M. P. 'Targeting hypoxia in cancer therapy.' Nature Reviews: Cancer 2011, 11, 393-410. (49) Teicher, B. A.; Lazo, J. S.; Sartorelli, A. C. 'Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells.' Cancer Research 1981, 41, 73-81. (50) Yoshiba, S.; Ito, D.; Nagumo, T.; Shirota, T.; Hatori, M.; Shintani, S. 'Hypoxia induces resistance to 5-fluorouracil in oral cancer cells via G(1) phase cell cycle arrest.' Oral Oncology 2009, 45, 109-115. (51) Kyle, A. H.; Huxham, L. A.; Yeoman, D. M.; Minchinton, A. I. 'Limited tissue penetration of taxanes: a mechanism for resistance in solid tumors.' Clinical Cancer Research 2007, 13, 2804-2810. (52) Gerweck, L. E.; Kozin, S. V.; Stocks, S. J. 'The pH partition theory predicts the accumulation and toxicity of doxorubicin in normal and low-pH-adapted cells.' British Journal of Cancer 1999, 79, 838-842. (53) Brophy, G. T.; Sladek, N. E. 'Influence of pH on the cytotoxic activity of chlorambucil.' Biochemical Pharmacology 1983, 32, 79-84. (54) Graeber, T. G.; Osmanian, C.; Jacks, T.; Housman, D. E.; Koch, C. J.; Lowe, S. W.; Giaccia, A. J. 'Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours.' Nature 1996, 379, 88-91. (55) Erler, J. T.; Cawthorne, C. J.; Williams, K. J.; Koritzinsky, M.; Wouters, B. G.; Wilson, C.; Miller, C.; Demonacos, C.; Stratford, I. J.; Dive, C. 'Hypoxia-mediated down-regulation of Bid and Bax in tumors occurs via hypoxia-inducible factor 1-dependent and -independent mechanisms and contributes to drug resistance.' Molecular and Cellular Biology 2004, 24, 2875-2889. (56) Bindra, R. S.; Glazer, P. M. 'Genetic instability and the tumor microenvironment: towards the concept of microenvironment-induced mutagenesis.' Mutation Research 2005, 569, 75-85. (57) Rice, G. C.; Hoy, C.; Schimke, R. T. 'Transient hypoxia enhances the frequency of dihydrofolate reductase gene amplification in Chinese hamster ovary cells.' Proceedings of the National Academy of Sciences of the United States of America 1986, 83, 5978-5982. (58) Bindra, R. S.; Glazer, P. M. 'Co-repression of mismatch repair gene expression by hypoxia in cancer cells: role of the Myc/Max network.' Cancer Letters 2007, 252, 93-103. (59) Yuan, J.; Narayanan, L.; Rockwell, S.; Glazer, P. M. 'Diminished DNA repair and elevated mutagenesis in mammalian cells exposed to hypoxia and low pH.' Cancer Research 2000, 60, 4372-4376. (60) Chan, N.; Koritzinsky, M.; Zhao, H.; Bindra, R.; Glazer, P. M.; Powell, S.; Belmaaza, A.; Wouters, B.; Bristow, R. G. 'Chronic hypoxia decreases synthesis of homologous recombination proteins to offset chemoresistance and radioresistance.' Cancer Research 2008, 68, 605-614. (61) Comerford, K. M.; Wallace, T. J.; Karhausen, J.; Louis, N. A.; Montalto, M. C.; Colgan, S. P. 'Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene.' Cancer Research 2002, 62, 3387-3394. (62) Wirthner, R.; Wrann, S.; Balamurugan, K.; Wenger, R. H.; Stiehl, D. P. 'Impaired DNA double-strand break repair contributes to chemoresistance in HIF-1 alpha-deficient mouse embryonic fibroblasts.' Carcinogenesis 2008, 29, 2306-2316. (63) Rischin, D.; Peters, L. J.; O'Sullivan, B.; Giralt, J.; Fisher, R.; Yuen, K.; Trotti, A.; Bernier, J.; Bourhis, J.; Ringash, J.; Henke, M.; Kenny, L. 'Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group.' Journal of Clinical Oncology 2010, 28, 2989-2995. (64) Jain, A.; Phillips, R. M.; Scally, A. J.; Lenaz, G.; Beer, M.; Puri, R. 'Response of multiple recurrent TaT1 bladder cancer to intravesical apaziquone (EO9): comparative analysis of tumor recurrence rates.' Urology 2009, 73, 1083-1086. (65) Duan, J. X.; Jiao, H.; Kaizerman, J.; Stanton, T.; Evans, J. W.; Lan, L.; Lorente, G.; Banica, M.; Jung, D.; Wang, J.; Ma, H.; Li, X.; Yang, Z.; Hoffman, R. M.; Ammons, W. S.; Hart, C. P.; Matteucci, M. 'Potent and highly selective hypoxia-activated achiral phosphoramidate mustards as anticancer drugs.' Journal of Medicinal Chemistry 2008, 51, 2412-2420. (66) Patterson, A. V.; Ferry, D. M.; Edmunds, S. J.; Gu, Y.; Singleton, R. S.; Patel, K.; Pullen, S. M.; Hicks, K. O.; Syddall, S. P.; Atwell, G. J.; Yang, S.; Denny, W. A.; Wilson, W. R. 'Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104.' Clinical Cancer Research 2007, 13, 3922-3932. (67) Patterson, L. H. 'Bioreductively activated antitumor N-oxides: the case of AQ4N, a unique approach to hypoxia-activated cancer chemotherapy.' Drug Metabolism Reviews 2002, 34, 581-592. (68) Danson, S. J.; Johnson, P.; Ward, T. H.; Dawson, M.; Denneny, O.; Dickinson, G.; Aarons, L.; Watson, A.; Jowle, D.; Cummings, J.; Robson, L.; Halbert, G.; Dive, C.; Ranson, M. 'Phase I pharmacokinetic and pharmacodynamic study of the bioreductive drug RH1.' Annals of Oncology 2011, 22, 1653-1660. (69) Papadopoulou, M. V.; Bloomer, W. D. 'NLCQ-1 (NSC 709257): exploiting hypoxia with a weak DNA-intercalating bioreductive drug.' Clinical Cancer Research 2003, 9, 5714-5720. (70) Hicks, K. O.; Siim, B. G.; Jaiswal, J. K.; Pruijn, F. B.; Fraser, A. M.; Patel, R.; Hogg, A.; Liyanage, H. D.; Dorie, M. J.; Brown, J. M.; Denny, W. A.; Hay, M. P.; Wilson, W. R. 'Pharmacokinetic/pharmacodynamic modeling identifies SN30000 and SN29751 as tirapazamine analogues with improved tissue penetration and hypoxic cell killing in tumors.' Clinical Cancer Research 2010, 16, 4946-4957. (71) Tercel, M.; Atwell, G. J.; Yang, S.; Ashoorzadeh, A.; Stevenson, R. J.; Botting, K. J.; Gu, Y.; Mehta, S. Y.; Denny, W. A.; Wilson, W. R.; Pruijn, F. B. 'Selective treatment of hypoxic tumor cells in vivo: phosphate pre-prodrugs of nitro analogues of the duocarmycins.' Angewandte Chemie. International Ed. In English 2011, 50, 2606-2609. (72) Baumann, R. P.; Penketh, P. G.; Ishiguro, K.; Shyam, K.; Zhu, Y. L.; Sartorelli, A. C. 'Reductive activation of the prodrug 1,2-bis(methylsulfonyl)-1-(2-chloroethyl)-2-[[1-(4-nitrophenyl)ethoxy]carbonyl]hy drazine (KS119) selectively occurs in oxygen-deficient cells and overcomes O(6)-alkylguanine-DNA alkyltransferase mediated KS119 tumor cell resistance.' Biochemical Pharmacology 2010, 79, 1553-1561. (73) Brown, J. M. 'SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours.' British Journal of Cancer 1993, 67, 1163-1170. (74) Chowdhury, G.; Junnotula, V.; Daniels, J. S.; Greenberg, M. M.; Gates, K. S. 'DNA strand damage product analysis provides evidence that the tumor cell-specific cytotoxin tirapazamine produces hydroxyl radical and acts as a surrogate for O(2).' Journal of the American Chemical Society 2007, 129, 12870-12877. (75) Shinde, S. S.; Hay, M. P.; Patterson, A. V.; Denny, W. A.; Anderson, R. F. 'Spin trapping of radicals other than the *OH radical upon reduction of the anticancer agent tirapazamine by cytochrome P450 reductase.' Journal of the American Chemical Society 2009, 131, 14220-14221. (76) Evans, J. W.; Chernikova, S. B.; Kachnic, L. A.; Banath, J. P.; Sordet, O.; Delahoussaye, Y. M.; Treszezamsky, A.; Chon, B. H.; Feng, Z.; Gu, Y.; Wilson, W. R.; Pommier, Y.; Olive, P. L.; Powell, S. N.; Brown, J. M. 'Homologous recombination is the principal pathway for the repair of DNA damage induced by tirapazamine in mammalian cells.' Cancer Research 2008, 68, 257-265. (77) Baker, M. A.; Zeman, E. M.; Hirst, V. K.; Brown, J. M. 'Metabolism of SR 4233 by Chinese hamster ovary cells: basis of selective hypoxic cytotoxicity.' Cancer Research 1988, 48, 5947-5952. (78) Minchinton, A. I.; Tannock, I. F. 'Drug penetration in solid tumours.' Nature Reviews: Cancer 2006, 6, 583-592. (79) Durand, R. E.; Olive, P. L. 'Physiologic and cytotoxic effects of tirapazamine in tumor-bearing mice.' Radiation Oncology Investigations 1997, 5, 213-219. (80) Durand, R. E.; Olive, P. L. 'Evaluation of bioreductive drugs in multicell spheroids.' International Journal of Radiation Oncology, Biology, Physics 1992, 22, 689-692. (81) Hicks, K. O.; Fleming, Y.; Siim, B. G.; Koch, C. J.; Wilson, W. R. 'Extravascular diffusion of tirapazamine: effect of metabolic consumption assessed using the multicellular layer model.' International Journal of Radiation Oncology, Biology, Physics 1998, 42, 641-649. (82) Kyle, A. H.; Minchinton, A. I. 'Measurement of delivery and metabolism of tirapazamine to tumour tissue using the multilayered cell culture model.' Cancer Chemotherapy and Pharmacology 1999, 43, 213-220. (83) Siim, B. G.; Pruijn, F. B.; Sturman, J. R.; Hogg, A.; Hay, M. P.; Brown, J. M.; Wilson, W. R. 'Selective potentiation of the hypoxic cytotoxicity of tirapazamine by its 1-N-oxide metabolite SR 4317.' Cancer Research 2004, 64, 736-742. (84) Garner, A. P.; Paine, M. J.; Rodriguez-Crespo, I.; Chinje, E. C.; Ortiz De Montellano, P.; Stratford, I. J.; Tew, D. G.; Wolf, C. R. 'Nitric oxide synthases catalyze the activation of redox cycling and bioreductive anticancer agents.' Cancer Research 1999, 59, 1929-1934. (85) Chinje, E. C.; Cowen, R. L.; Feng, J.; Sharma, S. P.; Wind, N. S.; Harris, A. L.; Stratford, I. J. 'Non-nuclear localized human NOSII enhances the bioactivation and toxicity of tirapazamine (SR4233) in vitro.' Molecular Pharmacology 2003, 63, 1248-1255. (86) Thomsen, L. L.; Miles, D. W.; Happerfield, L.; Bobrow, L. G.; Knowles, R. G.; Moncada, S. 'Nitric oxide synthase activity in human breast cancer.' British Journal of Cancer 1995, 72, 41-44. (87) Swana, H. S.; Smith, S. D.; Perrotta, P. L.; Saito, N.; Wheeler, M. A.; Weiss, R. M. 'Inducible nitric oxide synthase with transitional cell carcinoma of the bladder.' Journal of Urology 1999, 161, 630-634. (88) Lewis, C.; Murdoch, C. 'Macrophage responses to hypoxia: implications for tumor progression and anti-cancer therapies.' American Journal of Pathology 2005, 167, 627-635. (89) Melillo, G.; Musso, T.; Sica, A.; Taylor, L. S.; Cox, G. W.; Varesio, L. 'A hypoxia-responsive element mediates a novel pathway of activation of the inducible nitric oxide synthase promoter.' Journal of Experimental Medicine 1995, 182, 1683-1693. (90) Tendler, D. S.; Bao, C.; Wang, T.; Huang, E. L.; Ratovitski, E. A.; Pardoll, D. A.; Lowenstein, C. J. 'Intersection of interferon and hypoxia signal transduction pathways in nitric oxide-induced tumor apoptosis.' Cancer Research 2001, 61, 3682-3688. (91) Colucci, M. A.; Moody, C. J.; Couch, G. D. 'Natural and synthetic quinones and their reduction by the quinone reductase enzyme NQO1: from synthetic organic chemistry to compounds with anticancer potential.' Organic & Biomolecular Chemistry 2008, 6, 637-656. (92) Daniell, M. D.; Hill, J. S. 'A history of photodynamic therapy.' Australian and New Zealand Journal of Surgery 1991, 61, 340-348. (93) Ackroyd, R.; Kelty, C.; Brown, N.; Reed, M. 'The history of photodetection and photodynamic therapy.' Photochemistry and Photobiology 2001, 74, 656-669. (94) Dougherty, T. J.; Grindey, G. B.; Fiel, R.; Weishaupt, K. R.; Boyle, D. G. 'Photoradiation therapy. II. Cure of animal tumors with hematoporphyrin and light.' Journal of the National Cancer Institute 1975, 55, 115-121. (95) Kelly, J. F.; Snell, M. E.; Berenbaum, M. C. 'Photodynamic destruction of human bladder carcinoma.' British Journal of Cancer 1975, 31, 237-244. (96) Kelly, J. F.; Snell, M. E. 'Hematoporphyrin derivative: a possible aid in the diagnosis and therapy of carcinoma of the bladder.' Journal of Urology 1976, 115, 150-151. (97) Dougherty, T. J.; Kaufman, J. E.; Goldfarb, A.; Weishaupt, K. R.; Boyle, D.; Mittleman, A. 'Photoradiation therapy for the treatment of malignant tumors.' Cancer Research 1978, 38, 2628-2635. (98) Dougherty, T. J.; Lawrence, G.; Kaufman, J. H.; Boyle, D.; Weishaupt, K. R.; Goldfarb, A. 'Photoradiation in the treatment of recurrent breast carcinoma.' Journal of the National Cancer Institute 1979, 62, 231-237. (99) Mang, T. S.; Allison, R.; Hewson, G.; Snider, W.; Moskowitz, R. 'A phase II/III clinical study of tin ethyl etiopurpurin (Purlytin)-induced photodynamic therapy for the treatment of recurrent cutaneous metastatic breast cancer.' Cancer Journal from Scientific American 1998, 4, 378-384. (100) Dimofte, A.; Zhu, T. C.; Hahn, S. M.; Lustig, R. A. 'In vivo light dosimetry for motexafin lutetium-mediated PDT of recurrent breast cancer.' Lasers in Surgery and Medicine 2002, 31, 305-312. (101) Gomer, C. J.; Doiron, D. R.; Jester, J. V.; Szirth, B. C.; Murphree, A. L. 'Hematoporphyrin derivative photoradiation therapy for the treatment of intraocular tumors: examination of acute normal ocular tissue toxicity.' Cancer Research 1983, 43, 721-727. (102) Favilla, I.; Favilla, M. L.; Gosbell, A. D.; Barry, W. R.; Ellims, P.; Hill, J. S.; Byrne, J. R. 'Photodynamic therapy: a 5-year study of its effectiveness in the treatment of posterior uveal melanoma, and evaluation of haematoporphyrin uptake and photocytotoxicity of melanoma cells in tissue culture.' Melanoma Research 1995, 5, 355-364. (103) Landau, I. M.; Steen, B.; Seregard, S. 'Photodynamic therapy for circumscribed choroidal haemangioma.' Acta Ophthalmologica Scandinavica 2002, 80, 531-536. (104) Hill, J. S.; Kaye, A. H.; Sawyer, W. H.; Morstyn, G.; Megison, P. D.; Stylli, S. S. 'Selective uptake of hematoporphyrin derivative into human cerebral glioma.' Neurosurgery 1990, 26, 248-254. (105) Popovic, E. A.; Kaye, A. H.; Hill, J. S. 'Photodynamic therapy of brain tumors.' Journal of Clinical Laser Medicine and Surgery 1996, 14, 251-261. (106) Rosenthal, M. A.; Kavar, B.; Hill, J. S.; Morgan, D. J.; Nation, R. L.; Stylli, S. S.; Basser, R. L.; Uren, S.; Geldard, H.; Green, M. D.; Kahl, S. B.; Kaye, A. H. 'Phase I and pharmacokinetic study of photodynamic therapy for high-grade gliomas using a novel boronated porphyrin.' Journal of Clinical Oncology 2001, 19, 519-524. (107) Schweitzer, V. G. 'Photodynamic therapy for treatment of head and neck cancer.' Otolaryngology and Head and Neck Surgery 1990, 102, 225-232. (108) Biel, M. A. 'Photodynamic therapy and the treatment of head and neck neoplasia.' Laryngoscope 1998, 108, 1259-1268. (109) Barr, H.; Krasner, N.; Boulos, P. B.; Chatlani, P.; Bown, S. G. 'Photodynamic therapy for colorectal cancer: a quantitative pilot study.' British Journal of Surgery 1990, 77, 93-96. (110) Mlkvy, P.; Messmann, H.; Regula, J.; Conio, M.; Pauer, M.; Millson, C. E.; MacRobert, A. J.; Bown, S. G. 'Photodynamic therapy for gastrointestinal tumors using three photosensitizers--ALA induced PPIX, Photofrin and MTHPC. A pilot study.' Neoplasma 1998, 45, 157-161. (111) Allison, R. R.; Mang, T. S.; Wilson, B. D. 'Photodynamic therapy for the treatment of nonmelanomatous cutaneous malignancies.' Seminars in Cutaneous Medicine and Surgery 1998, 17, 153-163. (112) Taber, S. W.; Fingar, V. H.; Coots, C. T.; Wieman, T. J. 'Photodynamic therapy using mono-L-aspartyl chlorin e6 (Npe6) for the treatment of cutaneous disease: a Phase I clinical study.' Clinical Cancer Research 1998, 4, 2741-2746. (113) DeLaney, T. F.; Sindelar, W. F.; Tochner, Z.; Smith, P. D.; Friauf, W. S.; Thomas, G.; Dachowski, L.; Cole, J. W.; Steinberg, S. M.; Glatstein, E. 'Phase I study of debulking surgery and photodynamic therapy for disseminated intraperitoneal tumors.' International Journal of Radiation Oncology, Biology, Physics 1993, 25, 445-457. (114) Ortner, M. A.; Liebetruth, J.; Schreiber, S.; Hanft, M.; Wruck, U.; Fusco, V.; Muller, J. M.; Hortnagl, H.; Lochs, H. 'Photodynamic therapy of nonresectable cholangiocarcinoma.' Gastroenterology 1998, 114, 536-542. (115) Bown, S. G.; Rogowska, A. Z.; Whitelaw, D. E.; Lees, W. R.; Lovat, L. B.; Ripley, P.; Jones, L.; Wyld, P.; Gillams, A.; Hatfield, A. W. 'Photodynamic therapy for cancer of the pancreas.' Gut 2002, 50, 549-557. (116) Dolmans, D. E.; Fukumura, D.; Jain, R. K. 'Photodynamic therapy for cancer.' Nature Reviews: Cancer 2003, 3, 380-387. (117) Dougherty, T. J.; Gomer, C. J.; Henderson, B. W.; Jori, G.; Kessel, D.; Korbelik, M.; Moan, J.; Peng, Q. 'Photodynamic therapy.' Journal of the National Cancer Institute 1998, 90, 889-905. (118) Moan, J.; Berg, K. 'The photodegradation of porphyrins in cells can be used to estimate the lifetime of singlet oxygen.' Photochemistry and Photobiology 1991, 53, 549-553. (119) Henderson, B. W.; Waldow, S. M.; Mang, T. S.; Potter, W. R.; Malone, P. B.; Dougherty, T. J. 'Tumor destruction and kinetics of tumor cell death in two experimental mouse tumors following photodynamic therapy.' Cancer Research 1985, 45, 572-576. (120) Korbelik, M.; Krosl, G. 'Cellular levels of photosensitisers in tumours: the role of proximity to the blood supply.' British Journal of Cancer 1994, 70, 604-610. (121) Tromberg, B. J.; Orenstein, A.; Kimel, S.; Barker, S. J.; Hyatt, J.; Nelson, J. S.; Berns, M. W. 'In vivo tumor oxygen tension measurements for the evaluation of the efficiency of photodynamic therapy.' Photochemistry and Photobiology 1990, 52, 375-385. (122) Pogue, B. W.; Braun, R. D.; Lanzen, J. L.; Erickson, C.; Dewhirst, M. W. 'Analysis of the heterogeneity of pO2 dynamics during photodynamic therapy with verteporfin.' Photochemistry and Photobiology 2001, 74, 700-706. (123) Juarranz, A.; Jaen, P.; Sanz-Rodriguez, F.; Cuevas, J.; Gonzalez, S. 'Photodynamic therapy of cancer. Basic principles and applications.' Clinical & Translational Oncology 2008, 10, 148-154. (124) Fingar, V. H.; Wieman, T. J.; Haydon, P. S. 'The effects of thrombocytopenia on vessel stasis and macromolecular leakage after photodynamic therapy using photofrin.' Photochemistry and Photobiology 1997, 66, 513-517. (125) Fingar, V. H.; Kik, P. K.; Haydon, P. S.; Cerrito, P. B.; Tseng, M.; Abang, E.; Wieman, T. J. 'Analysis of acute vascular damage after photodynamic therapy using benzoporphyrin derivative (BPD).' British Journal of Cancer 1999, 79, 1702-1708. (126) Dolmans, D. E.; Kadambi, A.; Hill, J. S.; Waters, C. A.; Robinson, B. C.; Walker, J. P.; Fukumura, D.; Jain, R. K. 'Vascular accumulation of a novel photosensitizer, MV6401, causes selective thrombosis in tumor vessels after photodynamic therapy.' Cancer Research 2002, 62, 2151-2156. (127) Henderson, B. W.; Fingar, V. H. 'Relationship of tumor hypoxia and response to photodynamic treatment in an experimental mouse tumor.' Cancer Research 1987, 47, 3110-3114. (128) Chen, Q.; Chen, H.; Hetzel, F. W. 'Tumor oxygenation changes post-photodynamic therapy.' Photochemistry and Photobiology 1996, 63, 128-131. (129) Busch, T. M.; Wileyto, E. P.; Emanuele, M. J.; Del Piero, F.; Marconato, L.; Glatstein, E.; Koch, C. J. 'Photodynamic therapy creates fluence rate-dependent gradients in the intratumoral spatial distribution of oxygen.' Cancer Research 2002, 62, 7273-7279. (130) Henderson, B. W.; Fingar, V. H. 'Oxygen limitation of direct tumor cell kill during photodynamic treatment of a murine tumor model.' Photochemistry and Photobiology 1989, 49, 299-304. (131) Star, W. M.; Marijnissen, H. P.; van den Berg-Blok, A. E.; Versteeg, J. A.; Franken, K. A.; Reinhold, H. S. 'Destruction of rat mammary tumor and normal tissue microcirculation by hematoporphyrin derivative photoradiation observed in vivo in sandwich observation chambers.' Cancer Research 1986, 46, 2532-2540. (132) Wang, W.; Moriyama, L. T.; Bagnato, V. S. 'Photodynamic therapy induced vascular damage: an overview of experimental PDT.' Laser Physics Letters 2013, 10. (133) Henderson, B. W.; Dougherty, T. J. 'How does photodynamic therapy work?' Photochemistry and Photobiology 1992, 55, 145-157. (134) Shumaker, B. P.; Hetzel, F. W. 'Clinical laser photodynamic therapy in the treatment of bladder carcinoma.' Photochemistry and Photobiology 1987, 46, 899-901. (135) Gollnick, S. O.; Liu, X.; Owczarczak, B.; Musser, D. A.; Henderson, B. W. 'Altered expression of interleukin 6 and interleukin 10 as a result of photodynamic therapy in vivo.' Cancer Research 1997, 57, 3904-3909. (136) de Vree, W. J.; Essers, M. C.; de Bruijn, H. S.; Star, W. M.; Koster, J. F.; Sluiter, W. 'Evidence for an important role of neutrophils in the efficacy of photodynamic therapy in vivo.' Cancer Research 1996, 56, 2908-2911. (137) Jain, R. K. 'Delivery of molecular and cellular medicine to solid tumors.' Adv Drug Deliv Rev 2001, 46, 149-168. (138) Dougherty, T. J. 'An update on photodynamic therapy applications.' Journal of Clinical Laser Medicine and Surgery 2002, 20, 3-7. (139) Ruoslahti, E. 'Specialization of tumour vasculature.' Nature Reviews: Cancer 2002, 2, 83-90. (140) Bachor, R.; Shea, C. R.; Gillies, R.; Hasan, T. 'Photosensitized destruction of human bladder carcinoma cells treated with chlorin e6-conjugated microspheres.' Proceedings of the National Academy of Sciences of the United States of America 1991, 88, 1580-1584. (141) McBride, G. 'Studies expand potential uses of photodynamic therapy.' Journal of the National Cancer Institute 2002, 94, 1740-1742. (142) Puolakkainen, P.; Ramo, J.; Schroder, T. 'Photodynamic therapy in gastroenterology.' Scandinavian Journal of Gastroenterology 1990, 25, 417-421. (143) Webber, J.; Herman, M.; Kessel, D.; Fromm, D. 'Current concepts in gastrointestinal photodynamic therapy.' Annals of Surgery 1999, 230, 12-23. (144) Stupp, R.; Hegi, M. E.; Mason, W. P.; van den Bent, M. J.; Taphoorn, M. J.; Janzer, R. C.; Ludwin, S. K.; Allgeier, A.; Fisher, B.; Belanger, K.; Hau, P.; Brandes, A. A.; Gijtenbeek, J.; Marosi, C.; Vecht, C. J.; Mokhtari, K.; Wesseling, P.; Villa, S.; Eisenhauer, E.; Gorlia, T.; Weller, M.; Lacombe, D.; Cairncross, J. G.; Mirimanoff, R. O.; European Organisation for, R.; Treatment of Cancer Brain, T.; Radiation Oncology, G.; National Cancer Institute of Canada Clinical Trials, G. 'Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblasto | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/51206 | - |
dc.description.abstract | 光動力療法為常用之癌症治療方法之一,乃透過給予特定波段光源以活化光敏劑,並產生自由基及活性氧化物(如單氧分子),而引發細胞毒殺作用。然而光動力療法之效果常取決於病灶組織內氧氣濃度,在深層腫瘤區域普遍缺氧或因光動力治療而造成腫瘤處局部缺氧情形而使療效受限,導致癌細胞無法有效地被毒殺。目前針對治療深層腫瘤組織的缺氧區域,已有低氧性生物還原型前驅藥物(TPZ, Tirapazamine)被研發出來並進行臨床試驗中,癌細胞在吞噬該藥物後經由特定還原酵素活化即可產生毒殺的效果。因此本論文研究旨結合光動力治療及低氧性生物還原型前驅藥物,針對腫瘤內組織氧氣分布不均的環境進行治療,期待改善單一藥物在癌症治療上的效果。將光動力治療所造成的腫瘤環境氧氣濃度下降的缺點轉變為有利於低氧性生物還原型前驅藥物作用的微環境,希望藉此複合型治療策略提升癌細胞毒殺效率。本論文結果證實在正常氧壓(21% O2)的環境下,光動力治療所使用之光敏劑PpIX經由波長630 nm激發光活化後會消耗環境中的氧氣並產生單氧分子;且也發現氧氣濃度的降低至5%以下會提高該細胞內CYPOR還原酵素的活性。藉由在模擬實際腫瘤組織內氧氣濃度為5%、2%及1%的細胞實驗中,結果發現隨著氧氣濃度降低會造成光動力治療對細胞的毒殺能力下降,反之TPZ藥物對細胞的毒殺能力有上升趨勢。將兩種療法結合,則可在5%氧濃度環境下發揮協同毒殺作用,推測即為TPZ受到酵素催化形成的中間產物,在有氧的環境下會回復成原前驅形式藥物,伴隨接收電子後生成的超氧化物在細胞中造成毒性傷害。總結來說,本論文所觀察到的研究結果發現,根據腫瘤微環境氧氣濃度的分布而發展出的複合型治療法結合光動力治療和低氧性生物還原型前驅藥物TPZ應可為腫瘤治療策略上提供新的方向。 | zh_TW |
dc.description.abstract | Photodynamic therapy is one of the common medical treatments that uses a photosensitizer and a specific wavelength of light. When photosensitizers are exposed to a particular type of light, free radicals and singlet oxygen can be produced to subsequently kill nearby cells. However, photodynamic therapy fails to remove tumor cells completely in hypoxic tumor region or photodynamic therapy-induced hypoxia area.
To target hypoxia in cancer therapy, a hypoxia-specific drug Tirapazamine (TPZ) has been developed and currently in a number of phase III clinical trials, which is designed to be activated to a toxic free radical under hypoxia condition via the function of NADPH-cytochrome P450 reductase (CYPOR). Therefore, in current study we aimed to combine photodynamic therapy and bioreductive prodrug TPZ to treat cancer cells under biomimetic low oxygen environment to improve the limitation of therapeutic efficacy of a single drug. We expected that the combined therapy was able to turn the downside of photodynamic therapy-induced hypoxia into advantage, as bioreductive prodrug TPZ can be activated at low oxygen environment. The results showed that the tumor oxygenation was reduced and singlet oxygen was generated after photodynamic therapy. It was also observed that the low oxygenation levels in tumor microenvironment have significant difference on cellular CYPOR activity by comparing to normoxia condition (21% O2). In this study, 5%, 2%, 1% oxygenation levels were selected and used in cell culture experiments as biomimetric models of tumor microenvironmental oxygenation level. It was found that PDT remained cytotoxicity effect at 5% oxygen level, but reduced at 2% and 1% oxygen level. In contrast, the cytotoxicity effect of TPZ was activated on 1% oxygen level, but reduced at 2% and 5%oxygen level. Furthermore, the combination of PDT and TPZ prodrug demonstrated a synergistic killing of tumor cells under 5% oxygen level, which might be due to the back-oxidized of TPZ radical coupling with superoxide radical (O2-) production under oxygen present. In summary, our study showed that the newly-developed combined therapy based on the oxygenation feature of tumor microenvironment may provide a promising therapeutic strategy for cancer treatment. | en |
dc.description.provenance | Made available in DSpace on 2021-06-15T13:27:28Z (GMT). No. of bitstreams: 1 ntu-105-R02b22047-1.pdf: 4010261 bytes, checksum: d222835f117de70d346dbe3350ac82ca (MD5) Previous issue date: 2016 | en |
dc.description.tableofcontents | 謝誌 I
中文摘要 II Abstract III 目錄 V 圖目錄 VIII 表目錄 X 第1章 -文獻回顧 1 1.1 腫瘤缺氧環境 1 1.1.1 概論 1 1.1.2 缺氧成因 1 1.1.3 缺氧定義 3 1.1.4 分子層面的改變 4 1.1.5 治療策略 5 1.2 低氧性生物還原型前驅藥物 8 1.2.1 Tirapazamine 11 1.2.2 還原酶 13 1.3 光動力治療 15 1.3.1 發展概論 15 1.3.2 毒殺機制 18 1.3.3 影響光動力治療效率的因素 21 1.3.4 優勢與限制 22 1.3.5 Photoporphyrin IX 23 1.4 研究動機與實驗設計 26 第2章 -實驗方法 28 2.1 藥品材料與儀器 28 2.1.1 實驗藥品 28 2.1.2 實驗儀器 30 2.1.3 癌細胞株 31 2.1.4 氣體 31 2.1.5 光源架設與密封氣體袋製備 32 2.2 細胞培養 35 2.2.1 細胞繼代 35 2.2.2 細胞計數 36 2.2.3 細胞冷凍保存 36 2.3 細胞存活率測試 37 2.4 西方墨點法 38 2.4.1 細胞蛋白質萃取以及定量 38 2.4.2 蛋白質膠體電泳 39 2.4.3 蛋白質轉印以及抗體呈色 39 2.5 Cytochrome c Reductase (NADPH) 活性測試 40 2.6 溶氧測試 41 2.7 單氧偵測與溶氧偵測 43 第3章 -結果與討論 44 3.1 光敏劑受激發光活化後溶液中氧氣被消耗的情形 44 3.2 光敏劑受激發光活化後生成單態氧分子的定量分析 46 3.3 低氧環境下對細胞內生物還原酵素CYPOR活性的影響 49 3.4 光動力治療對毒殺癌細胞的結果 51 3.5 低氧型生物還原前驅藥物TPZ對癌細胞之毒殺作用 60 3.6 光動力治療搭配低氧型生物還原前驅藥物TPZ的複合療法 64 3.7 結論與未來展望 66 參考文獻 68 | |
dc.language.iso | zh-TW | |
dc.title | 新穎腫瘤治療法:發展以光動力治療法促進低氧性生物還原型前驅藥物之毒殺策略 | zh_TW |
dc.title | New tumor therapy: development of photodynamic therapy promoted bioreductive prodrug toxicity for cancer treatment | en |
dc.type | Thesis | |
dc.date.schoolyear | 104-1 | |
dc.description.degree | 碩士 | |
dc.contributor.coadvisor | 何佳安(Ja-An Ho) | |
dc.contributor.oralexamcommittee | 吳立真(Li-Chen Wu),徐士蘭(Shih-Lan Hsu),楊家銘(Chia-Ming Yang) | |
dc.subject.keyword | 光動力治療,腫瘤缺氧,低氧性生物還原型前驅藥物, | zh_TW |
dc.subject.keyword | photodynamic therapy,tumor hypoxia,bioreductive prodrug, | en |
dc.relation.page | 80 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2016-02-15 | |
dc.contributor.author-college | 生命科學院 | zh_TW |
dc.contributor.author-dept | 生化科技學系 | zh_TW |
顯示於系所單位: | 生化科技學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-105-1.pdf 目前未授權公開取用 | 3.92 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。